Literature DB >> 26663898

Right ventricular dysfunction and pulmonary hypertension following sub-massive pulmonary embolism.

Chinthaka B Samaranayake1, Gordon Royle2, Sharon Jackson2, Elaine Yap1.   

Abstract

BACKGROUND AND OBJECTIVES: Persistent right ventricular dysfunction (RVD) and pulmonary hypertension (PHT) are important outcomes following sub-massive pulmonary embolism (PE). The aims were to determine the rates and factors associated with RVD and/or PHT on echocardiography (ECHO) and the rate of 30-day and 1-year all-cause mortality following sub-massive PE. Patients who received thrombolysis and non-thrombolysis were also compared.
METHODS: Consecutive patients with sub-massive PE over a five year period with at least 1-year follow-up were retrospectively identified. Regression analysis was performed to identify predictors of outcomes.
RESULTS: Eighty-seven patients met inclusion criteria. Sixty-one (70%) had admission ECHOs with a follow-up ECHO in 42 (48.3%) at a mean of 7.6 months (SD 5.2). Fifty-one had RVD (58.6%) and 35 (40.2%) had PHT on admission. The rates of persistent RVD and raised right ventricular systolic pressure in this study population were 12% and 17%, respectively. Thrombolysis was associated with a trend towards improvement of PHT (53.3% PHT on admission to 0% PHT on follow-up in the thrombolysis group, P = 0.29). The rate of 30-day and 1-year all-cause mortality were 12.6% and 21.8%, respectively. Thirty-day all-cause mortality was independently predicted by the presence of right heart strain on computed tomography pulmonary angiography [OR 3.7 (P = 0.045)], echocardiographic evidence of RVD [OR 3.9 (P = 0.041)] and age.
CONCLUSION: The majority of patients with RVD and PHT at the time of sub-massive PE improve on follow-up; however, there is a subset who remain abnormal. Future studies are needed to identify modifiable risk factors for these complications.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  pulmonary hypertension; right ventricular dysfunction; sub-massive pulmonary embolism; thrombolysis

Mesh:

Year:  2016        PMID: 26663898     DOI: 10.1111/crj.12429

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  3 in total

Review 1.  Catheter-directed interventions for pulmonary embolism.

Authors:  Mehrzad Zarghouni; Hearns W Charles; Thomas S Maldonado; Amy R Deipolyi
Journal:  Cardiovasc Diagn Ther       Date:  2016-12

2.  Could HIF-1α be a novel biomarker for the clinical course and treatment of pulmonary embolism?

Authors:  Buğra Kerget; Dursun Erol Afşin; Alperen Aksakal; Seda Aşkin; Ömer Araz
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

3.  Quality of life and functional limitations after pulmonary embolism and its prognostic relevance.

Authors:  Karsten Keller; Clara Tesche; Aslihan Gerhold-Ay; Stefan Nickels; Frederikus A Klok; Lisa Rappold; Gerd Hasenfuß; Claudia Dellas; Stavros V Konstantinides; Mareike Lankeit
Journal:  J Thromb Haemost       Date:  2019-08-13       Impact factor: 5.824

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.